Sucampo Prices Public Offering of Common Stock by Selling Stockholders
March 26 2015 - 9:18AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced the pricing of an
underwritten public offering of 4,000,000 shares of its class A
common stock by selling stockholders, offered at a price to the
public of $14.00 per share for an aggregate offering of $56.0
million of class A common stock. All shares will be offered by
S&R Technology Holdings, LLC, S&R Foundation, Dr. Sachiko
Kuno and Dr. Ryuji Ueno. Sucampo will not sell any shares or
receive any proceeds from the offering. The underwriters have been
granted a 30-day option to purchase up to an aggregate of 600,000
additional shares of class A common stock. The offering is expected
to close on or about March 31, 2015, subject to customary closing
conditions.
Jefferies LLC and Leerink Partners LLC are acting as joint
book-running managers for the offering. Guggenheim Securities, LLC
is acting as co-manager.
A shelf registration statement on Form S-3 (including a
prospectus) and a preliminary prospectus supplement related to the
offering has been filed with the SEC. A final prospectus supplement
related to the offering will be filed with the SEC and will be
available on the SEC's website located at http://www.sec.gov.
Copies of the preliminary and final prospectus supplement and the
accompanying prospectus relating to this offering may be obtained
from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, via
telephone at 877-547-6340 or by email to
Prospectus_Department@Jefferies.com, or from Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, via telephone at 800-808-7525, ext. 6142 or by
email to syndicate@leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and
commercialization of medicines that meet major unmet medical needs
of patients worldwide. Sucampo has one marketed product – AMITIZA®
– and a pipeline of drug candidates in clinical development. A
global company, Sucampo is headquartered in Bethesda, Maryland, and
has operations in Japan, Switzerland and the United Kingdom.
The Sucampo logo is the registered trademark and the tagline,
The Science of Innovation, is a registered trademark of Sucampo
AG. AMITIZA is a registered trademark of Sucampo AG.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding market conditions and expectations with respect to the
proposed offering.
No forward-looking statement can be guaranteed and actual
results may differ materially from those projected. Sucampo
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk
factors and cautionary statements in Sucampo's most recent Annual
Report on Form 10-K as filed with the Securities and Exchange
Commission on March 9, 2015 as well as its filings with the
Securities and Exchange Commission on Form 10-Q and 8-K and as also
contained in the above-referenced prospectus, preliminary
prospectus supplement and final prospectus supplement.
CONTACT: Company Contact:
Silvia Taylor
SVP, Investor Relations and
Corporate Communications
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024